Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15034465 | 0.77 | MAOB (0.48) | POLBALDH1A1 | |
| SCHEMBL10481235 | 0.75 | MAPT (0.50) | MEN1MAPTKMT2APOLBL3MBTL1 | |
| SCHEMBL15034472 | 0.74 | — | — | |
| SCHEMBL7341085 | 0.70 | ALDH1A1 (0.44) | MEN1MAPTKMT2APOLBL3MBTL1 | |
| SCHEMBL6968157 | 0.70 | ALDH1A1 (0.44) | MEN1MAPTKMT2APOLBL3MBTL1 | |
| SCHEMBL11697163 | 0.70 | MAPT (0.53) | MEN1MAPTKMT2APOLBL3MBTL1 | |
| SCHEMBL10036507 | 0.67 | KMT2A (0.39) | MEN1MAPTKMT2APOLBL3MBTL1 | |
| SCHEMBL9130814 | 0.67 | MAPT (0.49) | MEN1MAPTKMT2APOLBL3MBTL1 | |
| SCHEMBL27195625 | 0.65 | MAPT (0.57) | MEN1MAPTKMT2APOLBL3MBTL1 | |
| SCHEMBL3022688 | 0.65 | ALDH1A1 (0.57) | MEN1MAPTKMT2APOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130157986-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | INVASC THERAPEUTICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157986-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | INVASC THERAPEUTICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157986-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | REN, PCSK9, COMT | MEN1 2495/4885MAPT 701/4885KMT2A 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.